Could CareTrust (CTRE) Stock Be a Top Healthcare REIT as Acquisition Growth Accelerates?

Could CareTrust (CTRE) Stock Be a Top Healthcare REIT as Acquisition Growth Accelerates?

Laiba Immad

Sat, August 29, 2026 at 12:55 AM GMT+3 3 min read

• CTRE -0.84%

CareTrust REIT, Inc. (NYSE:CTRE) caught market attention after delivering strong fiscal Q2 2026 operating results and raising its full-year 2026 guidance. The healthcare REIT now expects full-year normalized FFO per share of $2.03 to $2.06, placing the midpoint right in line with the $2.03 analyst consensus.

For Q2 2026, CareTrust reported total revenues of $161.34 million, surging 43% year-over-year. Normalized FFO surged 44% year-over-year to $119.7 million, translating to $0.51 per diluted share (up 19% year-over-year) and matching Wall Street estimates. Net income reached $89.0 million, or $0.38 per diluted share. The strong quarter was underpinned by record deployment, with YTD investments hitting roughly $1.5 billion at a blended yield of 8.7%.

On August 6, CareTrust extended its deal momentum by closing two transactions totaling $291 million. This included a $65 million acquisition of two senior housing communities in Utah (212 units) for its Senior Housing Operating Portfolio (SHOP), alongside a $226 million international acquisition of 16 care homes across England and Scotland.

15 States with the Best Healthcare in the US

However, Wall Street's reaction remains split. On August 14, RBC Capital analyst Michael Carroll downgraded CareTrust from Outperform to Sector Perform with a $43 price target (down from $44). While noting CTRE remains well positioned to deploy capital accretively, RBC shifted focus to peers that can directly leverage "strong fundamental tailwinds via organic growth."

This brings up a key question: Does CareTrust REIT, Inc. (CTRE)'s aggressive, yield-accretive deal deployment justify a premium valuation, or does its reliance on external financing and market cap-rate compression cap upside?

Bull Case

Bulls emphasize CareTrust's exceptional cash flow quality and fortress balance sheet. TTM free cash flow runs at ~97% of net income, providing robust internal funding for dividends and acquisitions without over-relying on volatile capital markets. Net debt to run-rate EBITDA sits at an enviable 1.01x, giving the company ultimate balance sheet flexibility and virtually zero near-term refinancing risk. Furthermore, CareTrust's active origination engine consistently sources high-spread deals, such as its record YTD deployment, fueling reliable double-digit FFO and FAD growth.

Bear Case

Bears point to funding execution and structural underwriting risks. Heavy reliance on unsettled equity forward contracts introduces volatility if market conditions soften prior to settlement. In the SHOP segment, intensifying competition has driven cap-rate compression, squeezing underwriting spreads and threatening future accretion on new acquisitions. Additionally, a material portion of CTRE's financing receivables includes long-dated purchase options, creating conversion timing uncertainty that complicates long-term cash flow predictability.

Insider Monkey's Hedge Fund Data Analysis

Hedge fund sentiment around CareTrust REIT, Inc. (NYSE:CTRE) turned increasingly positive in Q2 2026. Out of 1,006 funds tracked by Insider Monkey, 42 held positions in CTRE worth over $132 million, up from 36 funds in Q1 2026. D. E. Shaw holds the largest position, expanding its stake by 73% in Q2 to 1.82 million shares ($73.3 million), while Stuart J. Zimmer's Zimmer Partners holds 1.47 million shares ($59.4 million).

What Investors Should Watch Next

Investors should monitor the integration of recent U.K. and Utah acquisitions, trends in SHOP underwriting cap rates, and whether management can maintain its 8.5%+ deployment yield target without taking on unnecessary operator credit risk.

While we acknowledge the potential of CTRE as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on thebest short-term AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years

Disclosure: None. Follow Insider Monkey on Google News.